<DOC>
	<DOC>NCT01135511</DOC>
	<brief_summary>The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.</brief_summary>
	<brief_title>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Subjective symptoms of dry eye for at least 6 months Signs of moderate to severe dry eye (corneal staining score and schirmer test without anesthesia) Women who are nursing, pregnant or planning pregnancy during the study Participation in other studies within 30 days of screening visit Ocular disorders that may confound interpretation of study results</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dry eye</keyword>
</DOC>